We are constantly validating and improving our algorithm, to test its accuracy we collaborate with top hospitals.
In December 2017, clinical testing was performed to demonstrate the ability of the Embrace as a seizure monitoring aid.
During the clinical testing, 135 patients diagnosed with epilepsy were continuously monitored. This lead to 6,530 hours or 272.1 days of data, including 40 generalized tonic-clonic seizures. The trial was supervised by 3 board-certified clinical neurologists who independently examined the data. Embrace’s algorithm was shown to detect 93% of the seizures, The false alarm rate was 0.43 per day.
The full details of this work is included in this poster:
Lai,M., Regalia,G., Caborni,C., Tognetti,S., Onorati,F., Picard,R.(2018). Performance assessment of Embrace, the first FDA approved smartwatch for convulsive seizure detection. Partner Against Mortality in Epilepsy 2018